Edition:
India

Alexion Says FDA Grants Priority Review & Accepts sBLA Of SOLIRIS As Treatment For Patients With NMOSD


Saturday, 23 Feb 2019 

Feb 22 (Reuters) - Alexion Pharmaceuticals Inc ::FDA GRANTS PRIORITY REVIEW AND ACCEPTS SBLA OF SOLIRIS® (ECULIZUMAB) AS A TREATMENT FOR PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD).ALEXION PHARMACEUTICALS INC - FDA SETS ACTION DATE OF JUNE 28, 2019.ALEXION PHARMACEUTICALS INC - FILING IN EUROPEAN UNION UNDER REVIEW, AND FILING IN JAPAN PLANNED FOR Q1 2019.